Nafamostat

• CAT Number: I004959
• CAS Number: 81525-10-2
• Molecular Formula: C19H17N5O2
• Molecular Weight: 347.37
• Purity: ≥95%
• Synonyms: (6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate
• Target: Apoptosis
• Solubility: 10 mM in DMSO
• Storage: 2–8 °C
• InChI: InChI=1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24)
• InChIKey: MQQNFDZXWVTQEH-UHFFFAOYSA-N
• SMILES: C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N

Nafamostat（Cat No.:I004959） is a potent serine protease inhibitor with broad-spectrum activity. It acts as an inhibitor of kallikrein, a serine protease involved in various physiological and pathological processes. Additionally, nafamostat inhibits blood coagulation by interfering with factors in the coagulation cascade. It has also shown potential as a complement inhibitor, inhibiting the activation of the complement system involved in immune responses. The multifunctional properties of nafamostat make it a valuable compound for research and therapeutic applications in conditions such as sepsis, pancreatitis, and inflammatory disorders.

Reference

[1]. Ikehara S, et al. Effect of FUT-175, a new synthetic protease inhibitor, on the development of lupus nephritis in (NZB x NZW) F1 mice. Immunology. 1985 Aug;55(4):595-600.
[2]. Pak K, et al. Effectiveness of FUT-175, protease inhibitor, as an anticoagulant to hemodialysis. Hinyokika Kiyo. 1988 Jun;34(6):1077-81.